Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke.
An abundance of experimental data show that inflammation contributes to cerebral ischaemic injury and that attenuation of the inflammatory response can improve outcome. The two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy. The potential reasons for the failure of these trials are discussed.
D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules / Q000276:immunology / Q000378:metabolism; D002634:Chemotaxis, Leukocyte; D002986:Clinical Trials as Topic; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000276:immunology / Q000627:therapeutic use*; D007962:Leukocytes / Q000276:immunology*; D020521:Stroke / Q000628:therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules; D018799:Intercellular Adhesion Molecule-1; C115464:rovelizumab